Thank you, Madam Chair.
Thank you to all of our witnesses for appearing today.
Mr. Hawkswell, I'd like to direct my questions to you if I may. It's good to see you join our committee today. I really did appreciate how your comments were focused on a patient-centred approach. We, as a committee, have previously had Dr. Valorie Masuda appear before us, who's one of my constituents. She's a palliative care physician and she has seen first-hand with her patients how psilocybin in a controlled environment has definitely relieved their anxiety, the existential dread they feel when they are approaching the end of their life, and has allowed them to focus on that part of their life with friends and family present and with a much more sound mind.
You mentioned the research from Johns Hopkins. I'm just reading their website. I'll quote it:
Research to date [demonstrates] safety of psilocybin in regulated spaces facilitated by medical [teams] over a series of guided sessions; and as a part of cognitive behavioural therapy, psilocybin helps in reducing anxiety in some cancer patients, and in facilitating even smoking cessation for some.
Can you add a little bit more to what that research is pointing towards, and later on would you be able to submit some of that research to this committee so that we can consider it as we're approaching our final report?